EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Orosomucoid 2 as an immunometabolic regulator in cardiometabolic disease: Molecular mechanisms and translational potential

Xia Sun, Wen Shen, Xiang Tang, Cong Shen, Guoyue Yuan

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2026-11 · 1872 (8) · 168355

DOI: 10.1016/j.bbadis.2026.168355 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2026-11. Verfasst von Xia Sun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, 212013, China. Hauptthemen laut MEDLINE: Orosomucoid, Cardiovascular Diseases, Metabolic Diseases, Metabolic Syndrome. Die Arbeit nennt 97 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiometabolic diseases are driven by persistent crosstalk between metabolic dysfunction and chronic low-grade inflammation. Orosomucoid 2 (ORM2), a highly glycosylated acute-phase protein of the α1-acid glycoprotein family, has conventionally been considered a circulating inflammatory marker. Recent evidence, however, suggests that ORM2 may also function as an active immunometabolic regulator linking hepatic stress responses, adipose tissue inflammation, macrophage polarization, and systemic metabolic homeostasis. This review summarizes the molecular characteristics, tissue distribution, glycosylation-dependent biology, and stress-responsive regulation of ORM2, with emphasis on cytokine-induced JAK/STAT and NF-κB signaling, hepatic and extrahepatic ORM2 expression, and potential glycoform-specific regulation. Macrophage polarization is discussed as a central mechanism through which ORM2 may modulate inflammatory resolution, adipose-liver communication, insulin sensitivity, vascular inflammation, and myocardial injury. Particular attention is given to the possibility that increased ORM2 may represent a compensatory response to inflammatory-metabolic stress rather than simply a marker of disease burden. The translational potential of ORM2 is also considered, including its possible use in multi-marker biomarker panels for cardiometabolic risk stratification and treatment monitoring. However, major limitations remain, including incomplete mechanistic knowledge, unclear receptor biology, limited data on ORM2 glycosylation in specific cardiometabolic phenotypes, assay standardization issues, and insufficient prospective clinical validation. In summary, ORM2 appears to be a biologically plausible mediator linking inflammation and metabolism, but further mechanistic and clinical studies are required to establish its causal role, biomarker value, and therapeutic potential in cardiometabolic disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrosomucoidCardiovascular DiseasesMetabolic DiseasesMetabolic SyndromeHumansAnimalsBiomarkersInflammationSignal TransductionAdipose TissueLiverMacrophagesTranslational Research, Biomedical

Stichwörter der Autor:innen

Cardiometabolic diseaseImmunometabolismMacrophage polarizationMetabolic inflammationOrosomucoid 2

Substanzen

OrosomucoidBiomarkers

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, 212013, China.
  • Department of Endocrinology and Metabolism, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, 212013, China. Electronic address: yuanguoyue@ujs.edu.cn.

Zitieren

APA

Sun, X., Shen, W., Tang, X., Shen, C., & Yuan, G. (2026). Orosomucoid 2 as an immunometabolic regulator in cardiometabolic disease: Molecular mechanisms and translational potential. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1872(8), 168355. https://doi.org/10.1016/j.bbadis.2026.168355

Vancouver

Sun X, Shen W, Tang X, Shen C, Yuan G. Orosomucoid 2 as an immunometabolic regulator in cardiometabolic disease: Molecular mechanisms and translational potential. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2026;1872(8):168355. doi:10.1016/j.bbadis.2026.168355

BibTeX
@article{Sun2026,
  author = {Sun, Xia and Shen, Wen and Tang, Xiang and Shen, Cong and Yuan, Guoyue},
  title = {Orosomucoid 2 as an immunometabolic regulator in cardiometabolic disease: Molecular mechanisms and translational potential},
  journal = {Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease},
  year = {2026},
  volume = {1872},
  number = {8},
  pages = {168355},
  doi = {10.1016/j.bbadis.2026.168355}
}
Kostenlos starten →